Latest News

Washington, DC– Congressman Brett Guthrie (KY-02), vice chair of the House Committee on Energy and Commerce Subcommittee on Health, applauded President Trump’s signing of the Food and Drug Administration (FDA) Reauthorization Act of 2017 (H.R. 2430) into law last week. 

“I am very glad to see the FDA Reauthorization Act was signed into law by President Trump,”said Guthrie. “The user fee program reauthorized by this bill is key for faster and more efficient review of drugs and devices and ensures the FDA is fully funded with the resources to support highly qualified staff. It is more important than ever right now to foster innovation in the drug and device manufacturing industry.”

Guthrie, along with a bipartisan majority of members, voted to pass the FDA Reauthorization Act out of the Health Subcommittee in May. After passing the House in July, the bill passed the Senate on August 3rd with a 94 to 1 vote. 

Last year, Congress passed the 21st Century Cures Act, a groundbreaking bill that in part helped expedite the review process of new drugs and treatments for rare diseases. The FDA Reauthorization Act furthers this initiative by incentivizing more generic drugs to enter the market.

###